Gabriel N. Hortobagyi, MD, of The University of Texas MD Anderson Cancer Center, discusses the 8th edition of the TNM staging system, which includes prognostic stage groups based on clinical and pathologic factors combined with grade and hormone and HER2 status.
Joseph A. Sparano, MD, of Montefiore Medical Center, discusses phase III study results on chemoendocrine treatment vs endocrine treatment alone in hormone receptor–positive, HER2-negative, node-negative breast cancer and an intermediate prognosis 21-gene recurrence score (Abstract LBA1).
Bruce E. Johnson, MD, of the Lowe Center for Thoracic Oncology and ASCO’s outgoing President, talks with Monica M. Bertagnolli, MD, of Brigham and Women’s Hospital and the incoming President, about what has been achieved in the past year and what lies ahead.
Elizabeth A. Mittendorf, MD, PhD, of Dana-Farber/Brigham and Women’s Cancer Center, and Lisa A. Carey, MD, of the University of North Carolina, discuss the impact of new phase III findings on chemoendocrine treatment vs endocrine treatment alone in hormone receptor–positive, HER2-negative, node-negative breast cancer (Abstract LBA1).
Danh Pham, MD, of the James Graham Brown Cancer Center, University of Louisville, discusses his findings using a registry on the low rates of screening with low-dose computed tomography, despite its potential to prevent thousands of lung cancer deaths each year (Abstract 6504).
Ursula A. Matulonis, MD, of Dana-Farber Cancer Institute, and Stéphanie Gaillard, MD, PhD, of Duke Cancer Institute, discuss an evaluation of bevacizumab in the primary treatment of advanced ovarian cancer (Abstract 5517).
